United States · Bill · HR
H.R. 7032 (117th)
Increasing Transparency in Generic Drug Applications Act of 2022
Introduced
9 March 2022
Last action
—
Status
Referred to the Subcommittee on Health.
Sponsors
—
Subjects
Discovery layer
Source updated
7 April 2025
Summary
Increasing Transparency in Generic Drug Applications Act of 2022 This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 9 March 2022
Introduced in House (PDF)
Introduced in House · EN · 9 March 2022
Introduced in House
summary · EN · 9 March 2022
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/house-bill/7032
- Open data entity: https://api.congress.gov/v3/bill/117/hr/7032